key: cord-0961128-84g7z7re
authors: Jaspard, Marie; Sow, Mamadou Saliou; Juchet, Sylvain; Dienderé, Eric; Serra, Beatrice; Kojan, Richard; Sivahera, Billy; Martin, Caroline; Kinda, Moumouni; Lang, Hans-Joerg; Sako, Fodé Bangaly; Traoré, Fodé Amara; Koumbem, Eudoxie; Tinto, Halidou; Sanou, Adama; Sondo, Apoline; Kaboré, Flavien; Donamou, Joseph; Guilavogui, Jean-Paul-Yassa; Velardo, Fanny; Bicaba, Brice; Marcy, Olivier; Augier, Augustin; Sayadi, Sani; Poda, Armel; Keita, Sakoba; Anglaret, Xavier; Malvy, Denis
title: Clinical presentation, outcomes and factors associated with mortality: a prospective study from three COVID-19 referral care centers in West Africa
date: 2021-05-14
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.05.024
sha: 3fd3c24ee3d53572485de752a893c5ccc67172c5
doc_id: 961128
cord_uid: 84g7z7re

OBJECTIVES: In Africa, the overall death toll from COVID-19 is reported to be low but there is few individual-level evidence on the severity of the disease. We report the clinical spectrum and outcome of patients monitored in COVID-19 care centers (CCC) in two West-African countries. METHODS: Burkina Faso and Guinea set up referral CCCs to hospitalize all symptomatic SARS-CoV-2 carriers, regardless of the severity of their symptoms. We report the data collected from hospitalized patients by November 2020. RESULT: 1805 patients (64% men, median age 41) were admitted with COVID-19. Symptoms lasted for a median of 7 days (IQR 4-11). During hospitalization, 443 (25%) had at least once a SpO2 < 94%, 237 (13%) received oxygen and 266 (15%) corticosteroids. Mortality was 5% overall, and 1%, 5% and 14% in patients aged <40, 40-59 and ≥60. In multivariable analysis, the risk of death was higher in men (aOR 2.0, 95%CI 1.1;3.6), people aged ≥60 (aOR 2.9, 95%CI 1.7;4.8) and those with chronic hypertension (aOR 2.1, 95%CI 1.2;3.4). CONCLUSION: COVID-19 is as severe in Africa as elsewhere and common risk factors such as greater age and hypertension should make us vigilant.

As of May 5 th , 2021, it is estimated that 153 million people have been infected with SARS-CoV-2 and that COVID-19 has killed 3.2 million people worldwide. Africa accounts for only 3% of deaths from COVID-19, although 17% of the world's population lives there. Europe (10% of world population, 34% of deaths from and North America (4% of world population, 19% of deaths from COVID-19) have been impacted comparatively much higher. Dashboard, n.d.) Therefore, the death toll from COVID-19 seems actually lower in Africa than in Europe and North America, although some predictions indicated the opposite. (Martinez-Alvarez et al., 2020) This may be due to the heterogeneity of systems for reporting cases and causes of death, the level of preparedness in a continent that has faced threatening epidemics in the recent past, or differences in environmental characteristics, circulating strains or population susceptibility. (Galloway et al., 2020; Nagai et al., 2020; Price-Haywood et al., 2020; Williamson et al., 2020) To study this latter point, it would be useful to verify whether the clinical presentation, mortality, and factors associated with COVID-19 are similar in Africa to those described in other continents. There have been a few retrospective population or hospital-based cohorts reporting mortality rates from COVID-19 in Africa so far, but no cohorts that provide individual-level prospective evidence on the severity of the disease. (Abdela et al., 2020; Boulle et al., 2020; El Aidaoui et al., 2020; Elimian et al., 2020; Kirenga et al., 2020; Mekolo et al., 2021; Nachega et al., 2020) We report here clinical data collected prospectively on patients hospitalized in the COVID-19 referral care centers of two West African countries between March and November 2020.

Burkina Faso and Guinea, two West African countries, decided at the start of the pandemic to accommodate everyone detected as carriers of SARS-CoV-2 in specific centers, whether asymptomatic or symptomatic, and in the latter case regardless of the intensity of their symptom.

The Ministries of Health in the two countries set up the COVID-19 referral care centers in collaboration with the non-governmental association ALIMA (The Alliance for International Medical Action). In Guinea, the COVID-19 care center was opened at the Donka hospital in Conakry. In Burkina Faso, two COVID-19 care centers were opened at the Tengandogo and Clinique Princesse Sarah hospitals, in Ougadougou.

We describe here the data collected from all people hospitalized with symptomatic of COVID-19 and a positive RT-PCT SARS-CoV-2 test in each of these three centers. Those J o u r n a l P r e -p r o o f placed in isolation at the centers without having symptoms were excluded from this study.

The study period was between April 1 st and November 4 th 2020 in Guinea; and between March 1 st , 2020 and November 12 th 2020 in Burkina Faso.

All people received basic care for COVID-19 as defined in the recommendations of the ministries of health of the two countries. No additional medical action or treatment was introduced for participants in this study. Basic care was similar at the three centers. It included: (i) anti-infective treatment considered to have an anti-SARS-Cov-2 effect and recommended by the national authorities; (ii) oxygen therapy via nasal probe or mask, in the event of an SpO2 of <90%; and (iii) the possibility of corticosteroid therapy (methylprednisolone 120mg/d or dexamethasone 6 mg/d for 3 days then decrease over a total of 10 days), anticoagulant treatment (enoxaparin 100 IU/kg twice a day) and broadspectrum antibiotic therapy, of variable indication depending on the period and treating physician's decision.

Throughout the study, the anti-SARS-Cov-2 treatment recommended in the two countries consisted of a dual therapy combining 5 days of azithromycin (500 mg at day 1 and then 250 mg per day) with 10 days of hydroxychloroquine (200 mg x thrice a day). In Guinea, physicians had the choice of alternately using either hydroxychloroquine as monotherapy, lopinavir/ritonavir (200/50mg, twice a day for 10 days) as monotherapy or lopinavir/ritonavir in combination with hydroxychloroquine and azithromycin.

Each of the three centers contained an intensive care unit, allowing patients on oxygen to be closely monitored and non-invasive or mechanical ventilation to be used if required. In the context of the three urgently-established COVID-19 care centers, the data was first collected on hard copy CRF and subsequently entered in an electronic database. The variables considered essential for the analysis were then monitored and the source data verified. Only these variables are presented in this article. The variables are: patient verification (exhaustivity of the patient list); sex; age; comorbidities; date of first symptoms; signs, symptoms, measurement of pulse oximetry (SpO2) at baseline and during follow-up; oxygen therapy, anti-infectious treatments, corticosteroid therapy; and vital status at the end of follow-up. Radiological data, and biological data other than the result of the initial SARS-Cov2 test, were not monitored.

The follow-up time was the time between admission to hospital and death or discharge alive from hospital. There was no post-discharge follow-up. The primary endpoint was in-hospital death. The secondary endpoint was COVID-19 clinical worsening, defined as a combination of an SpO2 <94% at least once during follow-up (including at baseline), use of oxygen therapy at any time during follow-up, or death.

The analysis describes the baseline characteristics, care received during follow-up, outcomes, and factors associated with COVID-19 clinical worsening or death.

We used the Kaplan Meier method to estimate the probability of occurrence of the primary and secondary endpoint over time, overall and by sex, age category, and presence or absence of the main comorbidities.

We used univariable then multivariable logistic regression to analyze the association between the primary and secondary endpoint and the following characteristics: sex, age (<60 versus ≥60 years), time between first symptom and hospitalization (≤7 vs. >7 days), chronic hypertension declared by the patient (yes vs.no), diabetes declared by the patient (yes vs. no), and initial severity (in three grades, mild, moderate, severe, according to the May 2020 WHO definitions).(WHO, 2020) Variables associated with the endpoint with a p <0.20 in univariable analysis were included in the multivariable model.

The analyses were carried out using the software R, version 4.0.3

The study was approved in Burkina Faso by the Comité d'Ethique pour la Recherche en Santé (ID number 2020-6-116) and in Guinea by the Comité National d'Ethique pour la Recherche en Santé (ID number 069/CNERS/20).

The committees of the two countries authorized the use of medical data collection in accordance with WHO methodology to describe the course of the COVID-19 disease during routine care, without requesting signatures for specific consent.

The funding sources took no part in designing the study, collecting, analyzing and interpreting data, writing the report or making the decision to submit the article for J o u r n a l P r e -p r o o f publication. MJ, BS and SJ had access to the raw data. The corresponding author had full access to all the data and the final responsibility for submitting it for publication.

During the study period, 1938 people (Guinea: 1593; Burkina Faso: 345) were admitted to one of the three centers with a positive SARS-CoV2 PCR test on a nasopharyngeal swab. Of these, 133 were completely asymptomatic and were not included in the analysis. The remaining 1805 were included in the analysis (Guinea: 1593; Burkina Faso: 212).

Their baseline characteristics are detailed in Table 1 . Sixty-four percent of the participants were men and 36% women. The median age was 41 years (IQR 30-57, range 1-99 years). The two most common co-morbidities were chronic hypertension (21%) and diabetes (12%). The median weight was 73 kilograms (IQR 60-85). Height, and therefore body mass index (BMI), could only be measured in 645 people. In this subgroup, the median BMI was 25 kg/m 2 (IQR 22-29), and 119 (18%) had a BMI of ≥ 30 kg/m 2 . At the time of admission, symptoms lasted for a median of 7 days (IQR 4-11). The clinical picture was dominated by signs of lower respiratory tract involvement, present in 1110 (61%) patients. Digestive signs were present in 311 (17%) patients. 177 (10%) patients had an SpO2 initially measured of 90%, and 177 (10%) were considered severe from the start on the basis of this SpO2 or other signs of respiratory severity.

The follow-up characteristics are detailed in Table 2 . During hospitalization, 1697 people (95%) received at least one specific treatment recommended by national authorities, and 97 (5%) received none. The most common treatment was the hydroxychloroquine plus azithromycin combination, received by 1244 (73%) participants. Between admission and the J o u r n a l P r e -p r o o f end of follow-up, 231 people (13%) had a measured SpO2 of <90% at least once, 237 (13%) received oxygen and 266 (15%) received corticosteroids.

The rate of clinical worsening was 31% overall; 24% in women and 34% in men; 23%, in patients aged <60 and 57% in those ≥ 60; 59% in diabetics and 27% in non-diabetics; 51% in patients with self-declared chronic hypertension and 25% in those without hypertension.

Overall 86 (5%) patients died within a median of 5 days (IQR 2-10) of hospital admission.

The final percentage of deaths by group was: 3% in women and 6% in men; 0%, 1%, 5% and 14% in patients aged <20, between 20 and 39 years, between 40 and 59 and ≥ 60, respectively; 13% in diabetics and 4% in non-diabetics; 12% in patients with chronic hypertension and 3% in those without hypertension; and 26%, 3% and 2% in patients initially considered to be at a severe, moderate and mild stage, respectively. Patients below 60 years at admission accounted for 38% of death (33/86). For these patients, median age was 50 years (IQR 41-56), 60% were at a severe stage at admission and 32% and 36% had diabetes and chronic hypertension respectively.

In the primary analysis, the risk of death was significantly higher in men, patients aged 60 and over, those with chronic hypertension and those initially considered to be at a severe stage. The duration of symptoms prior to admission was not significantly associated with the risk of death (Table 3A ).

In the secondary analysis, male patients, those aged ≥60, those with chronic hypertension and those with diabetes had a higher risk of clinical worsening (Table 3B) .

Patients who recovered were discharged after a median of 11 days (IQR 8-16).

To our knowledge, this is the first African study describing the clinical presentation and the outcomes of COVID-19 among symptomatic patients monitored prospectively in specialist hospital care centers.

This study has strengths in that it provides partial answers to some of the questions surrounding COVID-19 in Africa, and weaknesses in that it leaves other questions unanswered.

In two West African countries where the policy was to hospitalize everyone with a positive SARS-Cov-2 RT-PCR test regardless of the severity of the clinical picture, 5% of symptomatic people who were hospitalized died. Mortality was 14% in patients aged 60 or more, and 26% in people with severe respiratory signs on admission. Although no comparisons can be made between hospitals in different countries with different hospitalization practices and levels of care, these figures are consistent with what has been described elsewhere (Lv et al., 2020; Olumade and Uzairue, 2021; Singer et al., 2020) and strongly suggest that COVID-19 is at least as serious in Africa as it is in other continents. (Boulle et al., 2020; Elimian et al., 2020; Kirenga et al., 2020; Nachega et al., 2020) If the reported death toll from COVID-19 is lower in Africa than in Europe or the USA, (Chilimuri et al., 2020; Galloway et al., 2020; Rossi et al., 2020; Zhou et al., 2020) it is probably not because the disease is less lethal in Africa. This reasoning is also compatible with the 2.8%, 9.2% and 13.2% mortality rates reported from retrospective population or hospital-based cohorts in South-Africa, Nigeria and the Democratic Republic of the Congo (Boulle et al., 2020; Elimian et al., 2020; Nachega et al., 2020) as well as the 5.6% of an African meta analysis. (Olumade and Uzairue, 2021) In the present study, the predominant clinical presentation was respiratory. Digestive signs and general signs, headaches, myalgia and asthenia were nevertheless quite frequent, as J o u r n a l P r e -p r o o f was a lack of taste and smell. Mortality was 2 times higher in people with hypertension, 2 times higher in men, and 3 times higher in people aged 60 or more. These clinical spectrum and factors associated with mortality are also consistent with what has been described elsewhere. (Boulle et al., 2020; El Aidaoui et al., 2020; Elimian et al., 2020; Guan et al., 2020; Huang et al., 2020; Kirenga et al., 2020; Nachega et al., 2020; Singer et al., 2020; Zhou et al., 2020) They emphasize the particular severity of the disease in groups at risk, in Africa as elsewhere, and the need to set up appropriate care to try to reduce the high mortality rate in these groups.

The first type of appropriate care is oxygen therapy. In the present study, participants received oxygen therapy when their SpO2 dropped below 90%, but few people with an SpO2 of between 90% and 93% did. Very few patients also benefited from non-invasive or invasive ventilation. It can be hypothesized that expanding the indications for oxygen therapy and increasing recourse to ventilation could have reduced mortality. (Baker et al., 2020) Regarding other ways to improve care, our data is of very limited value. The anti-infective treatments recommended in both countries and widely prescribed to patients in this study have not been proven effective so far. (Kaptein et al., 2020; Maisonnasse et al., 2020; RECOVERY Collaborative Group et al., 2020; Skipper et al., 2020) Our data do not provide any new insights in this regard. In the present study, a large percentage of patients received corticosteroids, but although this percentage is consistent with what could be expected based on SpO2 figures, we are unable to give more details on its duration or precise indications. In addition, the data do not allow comment on anything concerning elaborate management of the complications of the disease in its inflammatory phase, but since substantial resuscitation capacities are limited, there is little hope for improving survival this J o u r n a l P r e -p r o o f way. Hopes for therapy lean more toward intervention applied upstream, to prevent aggravation. Treatments of this nature are still experimental, and it would be important for African centers to participate in trials of new curative treatments.

Finally, this study is also limited as follows. Because it was carried out at the height of an emergency, the monitoring of collected data was limited to a small number of key variables to ensure the analysis provided solid descriptive elements. Since the number of variables was limited, the analysis of factors associated with outcomes probably suffered from confusion bias. Nevertheless, the analyses were consistent with what was known elsewhere, and this external consistency has the advantage of increasing confidence that the data are robust. We believe, therefore, that the main results, which are the overall and group mortality rates, are credible.

In conclusion, COVID-19 is a serious disease in Africa as it is elsewhere, men are more likely to experience complications than women, and certain common risk factors such as age, diabetes and hypertension should make us particularly vigilant in the event of COVID-19 in these countries. Further studies should now focus on finding ways to reduce mortality from COVID-19 in Africa, overall and in these at-risk groups.

The anonymized individual data and the data dictionary of the study will be made available to other researchers by Professor Denis Malvy (denis.malvy@chu-bordeaux.fr) after approval of a methodologically sound proposal and the signature of a data access agreement.

J o u r n a l P r e -p r o o f 

Clinical Profile and Treatment of COVID-19 Patients: Experiences from an Ethiopian Treatment Center

Essential care of critical illness must not be forgotten in the COVID-19 pandemic

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

Predictors of Mortality in Adults Admitted with COVID-19: Retrospective Cohort Study from New York City

Predictors of Severity in Covid-19 Patients in Casablanca

Patient characteristics associated with COVID-19 positivity and fatality in Nigeria: retrospective cohort study

A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study

Global COVID-19 clinical platform: rapid core case report form (CRF)

Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity

Characteristics and outcomes of admitted patients infected with SARS-CoV-2 in Uganda

Clinical characteristics and co-infections of 354 hospitalized patients with COVID-19 in Wuhan, China: a retrospective cohort study

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

COVID-19 pandemic in west Africa

Clinical and epidemiological characteristics and outcomes of patients hospitalized for COVID-19 in

Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo

Can we apply lessons learned from Ebola experience in West Africa for COVID-19 in lower income countries? Glob

Clinical characteristics of 4499 COVID-19 patients in Africa: A metaanalysis

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia

Cohort of Four Thousand Four Hundred Four Persons Under Investigation for COVID-19

Hospital and Predictors of ICU Care and Ventilation

Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial

Clinical management of COVID-19 -intermin guidance -WHO

COVID-19 Therapeutic Trial Synopsis -WHO R&D Blueprint

COVID-19) Dashboard. n

Factors associated with COVID-19-related death using OpenSAFELY

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Chronic cardiac disease (N=25, 1%), current smoking (N=12, 1%), chronic pulmonary disease (N=17, 1%), active or previous tuberculosis (N=23, 1%), asthma (N=39, 2%), asplenia (N=0, 0%), chronic kidney disease (N=13, 1%), malignant neoplasm (N=4, 0%), chronic hepatic disease (N=19, 1%)

Runny nose, nasal congestion, sneezing

Other signs or symptoms: confusion (N=18, 1%), seizure (N=6, 0%), conjunctivitis (N=7, 0%), skin rash (N=3, 0%), skin ulcer (N=1, 0%), Lymphadenopathy (N=3, 0%), Bleeding (N=1, 0%)

Symptomatic patients meeting the case definition for COVID-19 without evidence of viral pneumonia or hypoxia

Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) but no signs of severe pneumonia

Child with clinical signs of non-severe pneumonia (cough or difficulty breathing + fast breathing and/or chest indrawing) and no signs of severe pneumonia

Adolescent or adult with clinical signs of pneumonia (fever, cough, dyspnoea, fast breathing) plus one of the following: respiratory rate > 30 breaths/min; severe respiratory distress

N=number; %=percentage; IQR=interquartile range * Missing values: Specific drugs, n = 11; Time from admission to discharge

See reference (WHO, 2020b)

N=total number of patients in the category

CI: confidence interval cOR: crude Odds Ratio aOR: adjusted Odds Ratio : the Odds Ratios for

N=total number of patients in the category; n= number of patients in the category who had a SpO2<94%, received oxygen, or died CI: confidence interval cOR: crude Odds Ratio